本篇回應
Pei-Chi Lo 認為 含有錯誤訊息
引用自 Pei-Chi Lo 查核回應
■此訊息論述有誤。

①英國藥品和醫療產品監管署(MHRA)的確透過黃卡(Yellow Card)系統蒐集COVID-19疫苗的不良反映,並彙整為「vaccine analysis print」報告。

②在BNT的「vaccine analysis print」報告中的確有視力損傷與失明(Visual impairment and blindness)項目,以2022年9月22日的報告為例,反應失明175件、視力損傷494件。

③但須留意,依據英國政府官網,黃卡系統是任何醫療專業人員、一般民眾、藥廠只要懷疑疫苗導致不良反應皆可通報。也就是說,報告中提到的許多不良反應,尚未被認定與疫苗有直接關聯。

④英國政府官網亦明確載明,這份報告中的資訊【不能】代表與疫苗相關的潛在副作用,【不能】以此報告作為疫苗安全性與風險的結論。

■雖然轉傳訊息論述有誤,但在「Nature Public Health Emergency Collection」、「Ocular immunology and inflammation」期刊的確有施打BNT疫苗後的視力損傷相關個案報告,但由於報告皆有限制,是否確實為BNT疫苗的罕見副作用尚無定論,須謹慎看待。

資料佐證

【英國政府官網資料】

Annex 1 Vaccine Analysis Print
https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting#annex-1-vaccine-analysis-print

COVID-19 mRNA Pfizer- BioNTech vaccine analysis print(Report Run Date: 29-Sep-2022)
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1109924/Vaccine_Analysis_Print_Pfizer_BioNTech_COVID-19_vaccine_28.09.2022.pdf

【視力損傷相關個案報告】

Acute reduction of visual acuity and visual field after Pfizer-BioNTech COVID-19 vaccine 2nd dose: a case report
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176659/

A Case of Transient Visual Field Defect following Administration of Pfizer-BioNTech COVID-19 Vaccine
https://pubmed.ncbi.nlm.nih.gov/35404749/

Acute reduction of visual acuity and visual field after Pfizer-BioNTech COVID-19 vaccine 2nd dose: a case report

Long-term and rare adverse effects of COVID-19 vaccines are unknown. Hence, it is important to report them to improve the safety profile of the vaccines and enhance their use worldwide. Here, we descr

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176659/

A Case of Transient Visual Field Defect following Administration of Pfizer-BioNTech COVID-19 Vaccine - PubMed

Clinicians should be aware that patients can experience transient visual symptoms following COVID-19 vaccination.

https://pubmed.ncbi.nlm.nih.gov/35404749/

以上內容「Cofacts 真的假的」訊息回報機器人與查證協作社群提供,以 CC授權 姓名標示-相同方式分享 4.0 (CC BY-SA 4.0) 釋出,於後續重製或散布時,原社群顯名及每一則查證的出處連結皆必須被完整引用。